HIV-1 peptide-Major Histocompatibility Complex on allogeneic dendritic cells (HIV-1 pMHC on allo-DCs)

HIV-1 peptide-Major Histocompatibility Complex (MHC) complexes on allogeneic dendritic cells (DCs) represent a specialized immunotherapeutic entity designed to elicit robust cellular immune responses against HIV-1 (Lu et al., 2004, Nature Medicine). In this approach, dendritic cells are harvested from a donor (allogeneic) and loaded with specific HIV-1 peptides, typically derived from conserved regions of the Gag, Pol, or Env proteins (Andrieu et al., 2007, Expert Review of Vaccines). These peptides are presented on the DC surface within MHC Class I and Class II molecules, forming the primary recognition signal for the recipient's T-cell receptors (TCRs). The use of allogeneic cells provides a potent allogeneic effect, where the mismatch in human leukocyte antigens (HLA) acts as a natural adjuvant, stimulating a cytokine-rich environment that facilitates the priming and expansion of HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ helper T cells (Kundig et al., 1993, PNAS). This strategy is primarily investigated as a therapeutic vaccine for HIV-1 infection, aiming to enhance immune control over the viral reservoir and potentially achieve a functional cure (Macatangay & Rinaldo, 2015, Current HIV/AIDS Reports). Key therapeutic challenges include the risk of alloimmunization, where the patient develops antibodies against donor HLA, and the logistical requirements of donor-recipient matching and cell processing.

Other names

HIV-1 pMHC complexAllogeneic DC-presented HIV antigensHaploidentical dendritic cell-presented HIV peptidesAllo-DC HIV vaccine

Presentation of viral antigens to T-cell receptors to induce HIV-specific cytotoxic and helper T-cell responses, enhanced by the allogeneic effect.